|
|
{{if listFind(vars.channel_names, "MSIF News")}} {{endif}}  {{if listFind(vars.channel_names, "MSIF News")}} {{endif}} {{if listFind(vars.channel_names, "MSIF News")}} 
MSIF News
{{endif}}
|
{{if listFind(vars.channel_names, "People With MS News")}} {{endif}}  {{if listFind(vars.channel_names, "People With MS News")}} {{endif}} {{if listFind(vars.channel_names, "People With MS News")}} 
Profile of the Month
{{endif}}
|
{{if listFind(vars.channel_names, "Research News")}} {{endif}}  {{if listFind(vars.channel_names, "Research News")}} {{endif}} {{if listFind(vars.channel_names, "Research News")}} 
Research News
{{endif}}
|
{{if listFind(vars.channel_names, "MS Society News")}} {{endif}}  {{if listFind(vars.channel_names, "MS Society News")}} {{endif}} {{if listFind(vars.channel_names, "MS Society News")}} 
MS News
{{endif}}
|
|
|
|
Making Connections
|
{{if listFind(vars.channel_names, "MSIF News")}}
|
|
MSIF News
 |
 |
| Summaries of new MSIF activities, events, projects, programmes, resources, publications and more. |
|
|
|
|
{{endif}}
{{if listFind(vars.channel_names, "People With MS News")}}
|
|
Profile of the Month
|
|
| Summaries of news, views and achievements from people with MS around the world. |
|
|
|
|
{{endif}}
{{if listFind(vars.channel_names, "Research News")}}
|
|
Research News
|
|
| Summaries of all the latest research findings on MS selected by a team based at the Institute of Neurology, London. |
The OPTimization of interferon for MS study: 375 mug interferon beta-1b in suboptimal responders
The authors studied safety and effectiveness of high dose beta-interferon in people with MS who did not respond to standard treatment. They found that higher doses of beta-interferon were more effective in reducing inflammation on MRI but further studies are needed to see if this reduces relapses.
authors: Durelli L, Barbero P, Bergui M, Versino E, Bassano MA, Verdun E, Ferrero B, Rivoiro C, Ferrero C, Picco E, Ripellino P, Viglietti D, Giuliani G, Montanari E, Clerico M; for the OPTIMS Study Group
source: J Neurol. 2008 Sep 25 [Epub ahead of print]
read more
Interferon-beta(1b) in multiple sclerosis: effect on progression of disability and clinical markers of treatment response
This study compared progression of disability in people with relapsing-remitting MS on beta-interferon with a control group from years ago who were not taking treatment. They reported that interferon delayed progression of disability over five years, although this was not a placebo controlled trial. They also found that the number of relapses in the early years predicted early relapse on beta-interferon treatment.
authors: Carmona O, Casado V, Moral E, Alonso-Magdalena L, Martínez-Yélamos A, Martínez-Yélamos S, Martín-Ozaeta G, Arbizu T
source: Eur Neurol. 2008 Sep 27;60(6):279-284 [Epub ahead of print]
read more
Vanishing MS T2-bright lesions before puberty: a distinct MRI phenotype?
The authors studied MS in children. They found differences in the brain MRI appearances in those with earlier onset of disease. In particular in children with early onset, lesions were more likely to disappear over time.
authors: Chabas D, Castillo-Trivino T, Mowry EM, Strober JB, Glenn OA, Waubant E
source: Neurology 2008 Sep 30;71(14):1090-3
read more
Flupirtine as neuroprotective add-on therapy in autoimmune optic neuritis
The authors studied the effects of flupirtine, a treatment usually used for chronic pain, in animal models of optic neuritis. They found that this medication seemed to protect retinal nerve cells. Further studies are needed to assess its effects in MS.
authors: Sättler MB, Williams SK, Neusch C, Otto M, Pehlke JR, Bähr M, Diem R
source: Am J Pathol. 2008 Oct 2 [Epub ahead of print]
read more
|
|
|
|
{{endif}}
{{if listFind(vars.channel_names, "MS Society News")}}
|
|
MS News
|
|
| Summaries of MS news from websites around the world. |
|
{{endif}}
|
|
Tell a friend
The email you subscribed with us is {{print email}}
Within this newsletter the following options are available: MSIF News; People with MS News; Research News and MS Society News. To amend your options please login to the 'My world of MS' online community where you can also read diary entries from people affected by MS, leave your own diary entries and send messages to other users. You can also change your email address, contact details and subscribe to our free publications.
If you have an RSS News Reader you can get the latest news syndicated to you by copying the following link to your Reader: Syndicate.
If you do not want to receive future issues of this newsletter or if you have received this in error, please accept our apologies and simply unsubscribe here
Multiple Sclerosis International Federation
3rd Floor Skyline House, 200 Union Street, SE1 0LX
Tel: +44 (0) 20 7620 1911
Fax: +44 (0) 20 7620 1922
Registered Charity: 1105321
Email: info@msif.org
|
|
